Literature DB >> 17925902

Pharmacogenomics--the potential of genetically guided prescribing.

Ajeet Singh1.   

Abstract

BACKGROUND: Matching patients to effective tolerable medications can take months of trial and error. Genetic factors can strongly influence drug response. One of the potential clinical applications of the Human Genome Project is prediction of medication response--pharmacogenomics.
OBJECTIVE: This article reviews the emerging field of pharmacogenomics and its clinical potential using the example of antidepressant and anticoagulant medication prescribing. DISCUSSION: Growing evidence suggests genomic profiling for common variants in cytochrome P450 enzymes and transport systems involving serotonin, noradrenaline and the blood-brain barrier could inform antidepressant prescribing. Similarly, genetic testing for variants in cytochrome CYP2C9 and vitamin K epoxide reductase could inform decisions about prescribing warfarin. Large clinical trials to determine the clinical utility of this approach are required before pharmacogenomics enters routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17925902

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  7 in total

Review 1.  Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.

Authors:  Yoshiyuki Kojima; Shoichi Sasaki; Yutaro Hayashi; Gozoh Tsujimoto; Kenjiro Kohri
Journal:  Nat Clin Pract Urol       Date:  2009-01

2.  Warfarin pharmacogenomics.

Authors:  Jiayi Li; Shan Wang; Joseph Barone; Brian Malone
Journal:  P T       Date:  2009-08

3.  A service improvement project to review prescribing information provided by general practitioners for new referrals to a UK National Health Service hospital pain clinic: potential implications of CYP2D6 enzyme inhibition.

Authors:  Helen Radford; Pauline Fitzgerald; Stephen Martin; Mark I Johnson
Journal:  Br J Pain       Date:  2016-07-05

4.  Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.

Authors:  Jared T Hagaman; Brent W Kinder; Mark H Eckman
Journal:  Lung       Date:  2010-04       Impact factor: 2.584

Review 5.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

6.  Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report.

Authors:  Ajeet B Singh
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-08-31       Impact factor: 2.582

7.  Association of a common variant at 10q26 and benign prostatic hyperplasia aggressiveness in han chinese descent.

Authors:  Xin Gu; Tao Huang; Ding Xu; Liujian Duan; Yang Jiao; Jian Kang; S Lilly Zheng; Jianfeng Xu; Jielin Sun; Jun Qi
Journal:  Biochem Res Int       Date:  2013-08-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.